ko-947
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 6, 2017 (NCT03051035)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
MAP2K1 inhibitor
Mitogen-activated protein kinase; ERK1/ERK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1- Mol. weight
- 355.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650284 ↗
Also known as
- ko-947
- ko-947
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03051035 | Phase 1 | Apr 6, 2017 | Kura Oncology, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kura Oncology, Inc. | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1